Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

66.7K
Overview
66.7K
T Cell Types and Functions01:24

T Cell Types and Functions

942
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
942
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

944
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
944
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

735
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
735

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.

NPJ precision oncology·2026
Same author

Effect of Emergency Department Boarding on ICU Length of Stay and In-Hospital Mortality; A Retrospective Cohort Study.

Archives of academic emergency medicine·2025
Same author

CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Factors associated with contrast-associated acute kidney injury in an emergency department: A cohort study in Lebanon.

PloS one·2025
Same author

Mortality in a cohort of WTC-exposed law-enforcement officers compared to non-WTC law-enforcement officers.

International archives of occupational and environmental health·2025
Same author

Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.

Cancer discovery·2024

Related Experiment Video

Updated: May 30, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.1K

Engineering resilient CAR T cells for immunosuppressive environment.

Malak Khalifeh1, Huda Salman1

  • 1Brown Center for Immunotherapy. IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, 975 W. Walnut St., IB554A, Indianapolis, IN 46202, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|January 26, 2025
PubMed
Summary

Chimeric antigen receptor (CAR) T cell therapy shows promise beyond cancer for autoimmune diseases. Optimizing CAR T cell design and manufacturing is crucial to overcome challenges in diverse microenvironments for better therapeutic outcomes.

Keywords:
chimeric antigen receptor T therapyefficacyexhaustioninhibitory receptorspersistenceresistancetranscription factors

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

793

Related Experiment Videos

Last Updated: May 30, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.1K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

793

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Chimeric antigen receptor (CAR) T cell therapy, initially successful in cancer, is being investigated for autoimmune disorders.
  • Both the immunosuppressive tumor microenvironment (TME) and the inflammatory environment of autoimmune diseases pose challenges to CAR T cell survival and function.
  • Mechanisms of resistance, including T cell exhaustion and dysfunction, are influenced by the microenvironment and chronic antigen stimulation.

Purpose of the Study:

  • To review the impact of CAR T cell development and the tumor microenvironment (TME) on therapeutic outcomes.
  • To discuss strategies for improving CAR T cell efficacy, including alternative cell sources, multi-antigen targeting, and TME modulation.
  • To highlight the need for innovation in CAR T cell design and manufacturing to enhance efficacy and durability.

Main Methods:

  • Review of existing literature on CAR T cell therapy in cancer and autoimmune diseases.
  • Analysis of factors influencing CAR T cell function and resistance, including construct design and microenvironmental impacts.
  • Discussion of emerging strategies and future directions in CAR T cell therapy.

Main Results:

  • CAR T cell therapy faces challenges in both immunosuppressive (cancer) and inflammatory (autoimmune) microenvironments, leading to T cell exhaustion and dysfunction.
  • CAR construct design (co-stimulatory domains, hinge, transmembrane regions, promoters, binder affinity, on/off rate) significantly modulates CAR T cell performance.
  • In vitro development and manufacturing processes are critical for therapeutic success.

Conclusions:

  • Continued innovation in CAR T cell design and manufacturing is essential to overcome environmental challenges and improve therapeutic efficacy and durability.
  • Strategies such as alternative cell sources, multi-antigen targeting, and TME reengineering hold potential for enhancing CAR T cell therapy.
  • Addressing T cell exhaustion and dysfunction in diverse disease contexts is key for broader application of CAR T cell therapy.